PT - JOURNAL ARTICLE AU - Lucia Campos Pellanda AU - Eliana Márcia da Ros Wendland AU - Alan John Alexander McBride AU - Luciana Tovo-Rodrigues AU - Marcos Roberto Alves Ferreira AU - Odir Antônio Dellagostin AU - Mariangela Freitas da Silveira AU - Aluisio Jardim Dornellas de Barros AU - Pedro Curi Hallal AU - Cesar Gomes Victora TI - Sensitivity and specificity of a rapid test for assessment of exposure to SARS-CoV-2 in a community-based setting in Brazil AID - 10.1101/2020.05.06.20093476 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.06.20093476 4099 - http://medrxiv.org/content/early/2020/05/10/2020.05.06.20093476.short 4100 - http://medrxiv.org/content/early/2020/05/10/2020.05.06.20093476.full AB - Background While the recommended laboratory diagnosis of COVID-19 is a molecular based assay, population-based studies to determine the prevalence of COVID-19 usually use serological assays.Objective To evaluate the sensitivity and specificity of a rapid diagnostic test for COVID-19 compared to quantitative reverse transcription polymerase chain reaction (qRT-PCR).Methods We evaluated the sensitivity using a panel of finger prick blood samples from participants >18 years of age that had been tested for COVID-19 by qRT-PCR. For assessing specificity, we used serum samples from the 1982 Pelotas (Brazil) Birth Cohort participants collected in 2012 with no exposure to SARS-CoV-2.Results The sensitivity of the test was 77.1% (95% CI 66.6 - 85.6), based upon 83 subjects who had tested positive for qRT-PCR at least 10 days before the rapid diagnostic test (RDT). Based upon 100 sera samples, specificity was 98.0% (95% CI 92.9 - 99.8). There was substantial agreement (Kappa score 0.76) between the qRT-PCR results and the RDT.Interpretation The validation results are well in line with previous assessments of the test, and confirm that it is sufficiently precise for epidemiological studies aimed at monitoring levels and trends of the COVID-19 pandemic.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialObservational studyFunding StatementThis work started through the Data Committee created by the State of Rio Grande do Sul government to fight the COVID-19 pandemics. The tests used in the study have been provided by the Brazilian Ministry of Health. Financial support for for data collection was provided by UNIMED Porto Alegre, Instituto Cultural Floresta and Instituto Serrapilheira. None of these funding sources took any part in study conceptualization, data collection, analysis or manuscript preparation, reviewing, or in the decision to submit the article for publication.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to the sensitive nature of the questions asked in this study, survey respondents were assured raw data would remain confidential and would not be shared. Data not available / The data that has been used is confidential